The Foundation for Physical Therapy is pleased to announce that ActivaTek Inc,Salt Lake City, Gentiva Health Services Inc, Atlanta, and Kalypto Medical, Mendota Heights, MN, have joined the Foundation's Partners in Research, a program that recognizes corporations that support the Foundation's mission of advancing the physical therapy profession through scientifically based and clinically relevant research, doctoral scholarships, and fellowships.

"We welcome all three companies and appreciate their support of the Foundation's quest for increasing effective means of restoring mobility and vitality through physical therapy research," said Foundation President Richard K Shields, PT, PhD, FAPTA, in a statement. "We look forward to working with them to advance the future of the physical therapy profession."

ActivaTek Inc develops and markets drug delivery and other medical devices for physical therapy. "As an innovative drug-delivery company, supporting clinical research studies is extremely important to us," said Jamal Yanaki, CEO and founder of ActivaTek, Inc. "It is crucial that we continually support the Foundation, and work together in the common goal to provide excellent treatment modalities that will innovate and improve healing."

Gentiva Health Services Inc is a nationwide provider of comprehensive home health care services, delivering innovative, high-quality care to patients across the United States. "As a company focused on providing evidence-based outcomes for our patients in the home setting, Gentiva is proud to be a partner in the Foundation's forward-thinking mission," said Gentiva Vice President of Clinical Development Steve Allred, PT. "We feel strongly that this partnership helps us provide both a higher level of patient care and an environment where our physical therapists can grow professionally."

Kalypto Medical manufactures a medical device for negative pressure wound treatment. "We worked closely with the physical therapist community for clinical input in developing our new wound treatment medical device," said Phillip Vierling, CEO of Kalypto. "This collaborative effort between Kalypto and the PT-trained wound research leaders has allowed the company to more quickly develop a product that meets the needs of the mobile patient with wounds being treated in physical therapy and sets the stage for a continually developing clinical research relationship within the larger professional community."

[Source: APTA]